GENETIC ANALYSIS NK -60 (8V8) — Cash Flow-to-Debt Ratio
GENETIC ANALYSIS NK -60 (8V8) has a Cash Flow-to-Debt Ratio of 0.32x as of December 2025, meaning its operating cash flow of €8.04 Million could theoretically repay 0% of its total liabilities (€25.37 Million) in one year. See how much free cash does GENETIC ANALYSIS NK -60 generate to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
GENETIC ANALYSIS NK -60 Cash Flow-to-Debt Ratio (2021–2025)
Historical debt coverage capacity for GENETIC ANALYSIS NK -60 across 5 annual periods. Also explore net asset momentum of GENETIC ANALYSIS NK -60 to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for GENETIC ANALYSIS NK -60 (2021–2025)
Year-by-year debt coverage analysis for GENETIC ANALYSIS NK -60. For market capitalisation and broader financial context, see 8V8 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.09x | €2.40 Million | €25.37 Million | ▲ +116.2% |
| 2024 | -0.58x | €-11.62 Million | €19.88 Million | ▲ +27.1% |
| 2023 | -0.80x | €-17.23 Million | €21.49 Million | ▲ +16.4% |
| 2022 | -0.96x | €-19.46 Million | €20.28 Million | ▲ +60.4% |
| 2021 | -2.42x | €-27.62 Million | €11.40 Million | — |